Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD · Nasdaq

Relmada Therapeutics, Inc. (RLMD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Relmada Therapeutics, Inc. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 77 days

EPS estimate

-0.20

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-0.11 (+44.9%)
estimate -0.20
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.22 (-9.8%)
estimate -0.20
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
19 Mar 2026
EPS actual
-0.27 (-81.7%)
estimate -0.15
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-0.30 (+29.3%)
estimate -0.42
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Relmada Therapeutics beat consensus estimates in its latest earnings report, with EPS showing a $0.11 loss versus an estimated $0.1995 loss and revenue that met expectations at $0.00. In the prior report EPS missed estimates while revenue also met expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Sergio Traversa
Employees
17
IPO date
20 Jun 2014
ISIN
US75955J4022
Website
relmada.com

Frequently asked questions

When does Relmada Therapeutics, Inc. (RLMD) next report earnings?

Relmada Therapeutics, Inc. (RLMD) is scheduled to report earnings on November 5, 2026.

What was Relmada Therapeutics, Inc.'s most recent earnings date?

Relmada Therapeutics, Inc. (RLMD) last reported earnings on August 6, 2026.

Where is Relmada Therapeutics, Inc. stock listed?

Relmada Therapeutics, Inc. (RLMD) is listed on Nasdaq.